Table 1.
Published studies of risk-reducing salpingo-oophorectomy and cancer risk in BRCA1/2 mutation carriers*
| Study, first author, and year (reference) | Study design† | Patient source | No. with/without RRSO |
Reported follow-up | Mean age at breast cancer (y) | Mean age at ovarian cancer (y) | Mean age at RRSO (y) | ||
| BRCA1 | BRCA2 | BRCA1/2 | |||||||
| Rebbeck et al., 1999 (9) | RC | NAMC | 43/79 | NA | 43/79 | 5546 PY | B1: RRSO: 44.7 | NR | B1: 36.8 |
| B1: No RRSO: 43.4 | |||||||||
| Kauff et al., 2002 (10) | PC | SIS | 56/48 | 42/24 | 98/72 | 2.0 MYFU | B1/2: RRSO: 54.5 | B1/2: RRSO: 39.8 | B1/2: 48.1 |
| B1/2: No RRSO: 48.3 | B1/2: No RRSO: 51.2 | ||||||||
| Rebbeck et al., 2002 (8) | RC | IMC | 219/240 | 42/52 | 261/292 | 8.5 MYFU | B1/2: RRSO: 52.5 | B1/2: RRSO: 54.9 | B1/2: 42.0 |
| B1/2: No RRSO: 50.3 | B1/2: No RRSO: 50.3 | ||||||||
| Rutter et al., 2003 (17) | CC | ISMC | 5/168 | 0/56 | 5/223 | NA | NR | NR | NR |
| Eisen et al., 2005 (15) | CC | IMC | 129/2341 | 36/786 | 166/3139 | NA | B1: 38.9 | NR | NR |
| B2: 40.9 | |||||||||
| Kramer et al., 2005 (12) | PC | NAMC | 33/65 | NR | NR | 16.5 MYFU, 11,105 PY | B1: RRSO: 47.4 | NR | NR |
| B1: No RRSO: 46.5 | |||||||||
| Domchek et al., 2006 (13) | PC | IMC | 103/191 | 52/80 | 155/271 | 2.5 MYFU | B1/2, RRSO: 47.8 | B1/2: RRSO: 44.0 | B1/2: 44.8 |
| B1/2: No RRSO: 41.7 | B1/2: No RRSO: 48.3 | ||||||||
| Finch et al., 2006 (11) | RC | IMC | 834/546 | 207/233 | 1041/779 | 3.5 MYFU | NR | B1/2: RRSO: 51.1 | B1/2: 46.4 |
| B1/2: No RRSO: 53.8 | |||||||||
| Chang-Claude et al., 2007 (14) | RC | EMC | NR | NR | 55/1601 | 65,675 PY | B1/2: 50.1 | NR | NR |
| Kauff et al., 2008 (16) | PC | IMC | 325/173 | 184/110 | 509/283 | 3.2 MYFU | B1: RRSO: 49.8 | B1: RRSO: 46.4 | |
| B1: No RRSO: 44.0 | B1: No RRSO: 56.2 | B1: 46.2 | |||||||
| B2: RRSO: 52.5 | B2: RRSO: NA | B2: 48.8 | |||||||
| B2: No RRSO: 53.0 | B2: No RRSO: 64.0 | ||||||||
In all but one of the prospective cohort studies, women with a prior diagnosis of breast cancer were included for the ovarian endpoint. In Domchek et al. (13) all patients were unaffected with breast or ovarian cancer at the start of follow-up, as the study was designed to evaluate the impact of RRSO on cancer incidence as well as disease-specific and overall survival. B1 = BRCA1 mutation carriers; B2 = BRCA2 mutation carriers; B1/2 = combined BRCA1 or BRCA2 group; PC = prospective cohort; RC = retrospective cohort; CC = case–control; NAMC = North American Multicenter Cohort; SIS = single-institution study; IMC = International Multicenter Cohort; ISMC = Israeli Multicenter Cohort; EMC = European Multicenter Cohort; MYFU = mean years of follow-up; PY = person-years; NR = not reported; and NA = not applicable; RRSO = risk-reducing salpingo-oophorectomy.
In the original publications, the prospective and retrospective cohorts were analyzed by survival/failure time analysis methods; the case–control studies were analyzed by logistic regression.